{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-045015","form_type":"8-K","ticker":"HYPD","cik":"0001682639","company_name":"HYPERION DEFI, INC.","filed_at":"2024-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.571696+00:00","generated_at":"2026-06-04T00:59:30.333736+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Eyenovia raises ~$2.0M in registered direct offering at $0.6204/share","bullets":["Sold 3,223,726 shares at $0.6204/share to a single healthcare investor; gross proceeds ~$2.0M.","Net proceeds to fund commercialization of Mydcombi and clobetasol propionate, complete CHAPERONE study.","Offering expected to close on or about April 11, 2024, subject to customary conditions.","Shares issued under existing effective shelf registration statement (No. 333-261638)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-045015","json":"https://secwatch.observer/filing/0001104659-24-045015.json","markdown":"https://secwatch.observer/filing/0001104659-24-045015.md","text":"https://secwatch.observer/filing/0001104659-24-045015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682639/000110465924045015/0001104659-24-045015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682639/000110465924045015/tm2411385d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:59:30.333736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"223dd96b41e688425ccc435247b2869878efb070","claim":"HYPERION DEFI, INC. entered into Purchase Agreement with a single fundamentals-based healthcare investor valued at approximately $2.0 million (effective 2024-04-08).","evidence_excerpt":"On April 8, 2024, Eyenovia, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single fundamentals-based healthcare investor (the “Purchaser”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1682639/000110465924045015/0001104659-24-045015-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a single fundamentals-based healthcare investor"},{"label":"Value","value":"approximately $2.0 million"},{"label":"Effective","value":"2024-04-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}